Genetic and chemical modulation of spastin-dependent axon outgrowth in zebrafish embryos indicates a role for impaired microtubule dynamics in hereditary spastic paraplegia

Richard Butler1,*,‡, Jonathan D. Wood1,2,*,§, Jennifer A. Landers1 and Vincent T. Cunliffe1,§

SUMMARY

Mutations in the SPAST (SPG4) gene, which encodes the microtubule-severing protein spastin, are the most common cause of autosomal dominant hereditary spastic paraplegia (HSP). Following on from previous work in our laboratory showing that spastin is required for axon outgrowth, we report here that the related microtubule-severing protein katanin is also required for axon outgrowth in vivo. Using confocal time-lapse imaging, we have identified requirements for spastin and katanin in maintaining normal axonal microtubule dynamics and growth cone motility in vivo, supporting a model in which microtubule severing is required for concerted growth of neuronal microtubules. Simultaneous knockdown of spastin and katanin caused a more severe phenotype than did individual knockdown of either gene, suggesting that they have different but related functions in supporting axon outgrowth. In addition, the microtubule-destabilising drug nocodazole abolished microtubule dynamics and growth cone motility, and enhanced phenotypic severity in spastin-knockdown zebrafish embryos. Thus, disruption of microtubule dynamics might underlie neuronal dysfunction in this model, and this system could be used to identify compounds that modulate microtubule dynamics, some of which might have therapeutic potential in HSP.

INTRODUCTION

The hereditary spastic paraplegias (HSPs) are a collection of neurodegenerative disorders characterised by progressive lower-limb spasticity and caused by the developmental failure or degeneration of upper motor axons in the corticospinal tract (Crosby and Proukakis, 2002; Reid, 2003). Mutations in the SPAST gene (also known as SPG4) are the most common cause of autosomal dominant HSP, and spastin (the SPAST gene product) is a microtubule-severing ATPase (Evans et al., 2005; Roll-Mecak and Vale, 2005; Salinas et al., 2005) that shares sequence and functional similarity with the p60 subunit of katanin (P60-katanin). Genetic and biochemical studies have demonstrated that SPAST mutations cause loss of spastin function, making haploinsufficiency a likely disease mechanism (Charvin et al., 2003; Evans et al., 2005; Patrono et al., 2002), although dominant-negative effects could contribute to disease pathogenesis in some cases (Errico et al., 2002; McDermott et al., 2003). To investigate the developmental requirements for spastin, we previously used morpholino antisense methods to knockdown spast expression in the zebrafish embryo and demonstrated a crucial requirement for spastin to promote axon outgrowth during embryonic development (Wood et al., 2006).

SPAST HSP cases are characterised by variability in the age of onset both between and within pedigrees (Durr et al., 1996), suggesting that other factors are important in defining disease severity. Similar to the function that we have shown for spastin in the zebrafish embryo, the microtubule-severing activity of P60-katanin is required to promote axon outgrowth in isolated mammalian sympathetic neurons (Ahmad et al., 1999; Karabay et al., 2004). We therefore hypothesised that P60-katanin might act as a modifier of spastin function in vivo. To address this possibility, we used morpholino antisense methods to determine the effect of reduced P60-katanin activity on axon outgrowth in the zebrafish embryo. We also investigated the effect of simultaneous knockdown of spastin and P60-katanin to give insight into the mechanistic relationship between the functions of these two microtubule-severing proteins.

Given that spastin and P60-katanin are microtubule-severing proteins with known roles in promoting axon outgrowth, we hypothesised that their activities might be required for axonal microtubule dynamics. When fused to green fluorescent protein (GFP), proteins that bind to microtubule plus-ends, such as end-binding protein 3 (EB3), are powerful markers for visualising microtubule growth events in cultured neurons (Stepanova et al., 2003); these proteins have been termed microtubule-plus-end-tracking proteins (+TIPs). We have developed methods for in vivo analysis of axonal microtubule dynamics in the zebrafish embryo using an EB3-GFP fusion protein, and used these methods to investigate the roles of spastin and katanin in axonal microtubule dynamics. We have also utilised this approach to investigate the effects of microtubule-destabilising drugs on axonal microtubule dynamics in zebrafish embryonic neurons. The findings from these studies suggest a model whereby the microtubule-severing
activities of spastin and katanin support the concerted growth of microtubules during embryonic development.

RESULTS

Like spastin, P60-katanin is required for axon outgrowth in the zebrafish embryo

We previously demonstrated a crucial requirement for spastin to promote axon outgrowth in the zebrafish embryo (Wood et al., 2006). Interestingly, the closely related microtubule-severing protein P60-katanin has also been shown to promote axonal growth in cultured primary neurons (Ahmad et al., 1999; Karabay et al., 2004). We therefore hypothesised that the microtubule-severing activity of P60-katanin might also be required for axon outgrowth in the zebrafish embryo. Ensembl (http://www.ensembl.org/index.html) identified ENSDARG00000021827 (zgc:110580) as the zebrafish orthologue of human KATNA1 (encoding katanin p60 subunit A1), which we refer to here as katna1. The predicted protein product of this gene shares 75% identity and 84% similarity with the human KATNA1-201 variant. The human genome also contains two related genes – the p60 katanin subunit A-like genes KATNAL1 and KATNAL2 – both of which have predicted zebrafish orthologues (zgc:101696 and zgc:123350, respectively); these zebrafish orthologues share lower similarity with human KATNA1 than does zgc:110580.

In order to determine whether reduced levels of P60-katanin affect motor axon outgrowth, embryos were microinjected at the one-cell stage either with a morpholino designed to specifically inhibit translation of katna1 mRNA (katna1aug1) or with a control morpholino (CoMO), and analysed by immunostaining with monoclonal antibody znp-1, which reveals the overall morphology of differentiating spinal motor neurons. This analysis demonstrated that inhibition of katna1 with katna1aug1 dramatically impaired outgrowth of motor axons from the spinal cord in a dose-dependent manner (Fig. 1A-D; Table 1). The majority of embryos injected with 0.9 pmol katna1aug1 (57.6%, n=97) showed mild defects in spinal motor axon outgrowth, whereas most embryos injected with 1.8 pmol katna1aug1 (91.5%, n=106) showed moderate or severe defects.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uninjected (n=125)</td>
<td>94.4</td>
<td>4.0</td>
<td>1.6</td>
<td>0</td>
</tr>
<tr>
<td>1.8 pmol CoMO (n=99)</td>
<td>62.6</td>
<td>22.2</td>
<td>12.1</td>
<td>3.1</td>
</tr>
<tr>
<td>0.9 pmol katna1aug1 (n=97)</td>
<td>11.3</td>
<td>57.6</td>
<td>21.6</td>
<td>8.3</td>
</tr>
<tr>
<td>1.8 pmol katna1aug1 (n=106)</td>
<td>0.9</td>
<td>7.5</td>
<td>44.3</td>
<td>47.2</td>
</tr>
<tr>
<td>Uninjected (n=57)</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0.9 pmol CoMO (n=16)</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1.8 pmol CoMO (n=56)</td>
<td>98.2</td>
<td>0</td>
<td>0</td>
<td>1.8</td>
</tr>
<tr>
<td>0.9 pmol katna1e4i4 (n=52)</td>
<td>23.1</td>
<td>40.4</td>
<td>26.9</td>
<td>9.6</td>
</tr>
<tr>
<td>1.8 pmol katna1e4i4 (n=63)</td>
<td>7.9</td>
<td>9.5</td>
<td>3.2</td>
<td>79.4</td>
</tr>
</tbody>
</table>

*Data pooled from three separate independent experiments for both katna1aug1 and katna1e4i4.

Fig. 1. Morpholino-mediated knockdown of katna1 function with a translation-blocking (katna1aug1) morpholino inhibits spinal motor axon outgrowth. Embryos were injected with 1.8 pmol of control (CoMO) (B), 0.9 pmol of katna1aug1 (C) or 1.8 pmol of katna1aug1 morpholino (D), fixed at 28 hpf, and then immunostained with znpi-1. An un.injected control is shown in A. The effects of katna1 and spast translation-blocking morpholinos on spinal motor axon outgrowth are independent of p53 (E). Axons were measured in embryos injected with 1.0 pmol CoMO + 1.6 pmol p53-specific morpholino (p53MO) (n=20), 0.6 pmol spg4atg1 + 1.2 pmol p53MO (n=21), or 1.0 pmol katna1aug1 + 1.6 pmol p53MO (n=17). Statistical significance was determined using ANOVA with Bonferroni’s multiple comparison test. ***P<0.001. (F) Immunoblots for katna1 and tubulin demonstrating that katna1aug1-injected embryos have reduced levels of katna1 protein compared with CoMO-injected embryos. (G) Immunoblots for spastin and tubulin demonstrating that spg4atg1-injected embryos show reduced levels of spastin protein compared with CoMO-injected embryos. The right panel in F and G is a section from an equivalently loaded Coomassie-blue-stained gel to demonstrate relative loadings. Scale bars: 50 μm.
defects. Immunoblotting for katna1 and spastin confirmed that the katna1aug1 and spg4atg1 morpholinos reduced katna1 (Fig. 1F) and spastin (Fig. 1G) protein levels, respectively. Similarly, a katna1 splice-blocking morpholino (katna1e4i4) also inhibited spinal motor axon outgrowth (Fig. 2B) and this effect was dose dependent (Table 1). Reverse-transcriptase polymerase chain reaction (RT-PCR) analysis demonstrated that the severity of the axon outgrowth defects in katna1e4i4 morphants correlated with the appearance of a smaller PCR product and a reduction in the amount of the larger cDNA fragment that was present in the control-injected embryos (supplementary material Fig. S1). These results are consistent with the splice morpholino causing skipping of exon 4, which would give rise to an mRNA encoding a truncated protein comprising a P60-katanin 102-residue N-terminal fragment up to Arg102 followed by a novel 9-residue tail, and lacking residues 103-485. Such a truncated P60-katanin polypeptide would lack the ATPase activity encoded by its AAA domain and thus have either no function or potentially dominant-negative effects.

Some morpholinos can elicit off-target developmental abnormalities in the central nervous system (CNS) of zebrafish embryos through the activation of a p53-dependent cell death pathway (Robu et al., 2007). To ascertain whether the motor axon outgrowth phenotype induced by katna1 morpholinos was due to such off-target effects, we co-injected a molar excess of a p53-specific morpholino (p53MO) with both katna1-specific morpholinos and the control morpholino and measured mean motor axon lengths in znp-1-stained embryos. With 1.0 pmol of katna1aug1 together with 1.6 pmol p53MO, and with 0.8 pmol katna1e4i4 together with 1.6 pmol p53MO, mean axon lengths were 78% and 65%, respectively, of the mean length in embryos injected with 1.0 pmol CoMO together with 1.6 pmol p53MO (Fig. 1E, Fig. 2D). We therefore conclude that reduced levels of katna1 expression caused spinal motor axon outgrowth defects in vivo. We also demonstrated that the effects of the spg4atg1 and spg4e7i7 morpholinos (Wood et al., 2006) on spinal motor axon outgrowth were independent of p53 (Fig. 1E, Fig. 2C,D). We previously found that spastin knockdown had widespread effects on axon outgrowth and was not restricted to spinal motor axons. Similarly, the effect of katna1 knockdown on axon outgrowth was not restricted to spinal motor neurons: reduced znp-1 staining was apparent throughout the spinal cord, suggesting that multiple populations of spinal interneurons were also affected.

**P60-katanin and spastin are required for axonal microtubule dynamics**

In order to investigate the mechanisms by which the microtubule-severing activities of spastin and P60-katanin promote axon outgrowth, we developed methods for in vivo analysis of microtubule growth events. We constructed the plasmid NBT:EB3-GFP, in which an expression cassette encoding an EB3-GFP fusion protein (Stepanova et al., 2003) was placed under the control of the Xenopus neural-specific β-tubulin (NBT) promoter. Microinjection of this construct into one- to two-cell zebrafish embryos gave a mosaic pattern of GFP expression that was specifically restricted to a scattered population of CNS neurons and more faintly expressing muscle cells, and yielded embryos in which individual EB3-GFP-expressing neurons could be readily visualised and imaged in their normal location within the developing CNS (supplementary material Fig. S2A). At higher magnification, punctate labelling was observed at regular intervals in axons (supplementary material Fig. S2B). Time-lapse confocal imaging demonstrated that these punctate comet-like regions of fluorescence moved in an anterograde direction away from the cell body (supplementary material Fig. S3A and Movie 1). This is clearly illustrated in the kymograph (supplementary material Fig. S3B). Kymography further revealed that the comets moved with a remarkably uniform average velocity of 0.14±0.2 μm/second.

To determine the effect of spastin and katna1 knockdown on axonal microtubule dynamics, NBT:EB3-GFP DNA was co-injected into one-cell-stage zebrafish embryos with spastin and katna1 translation- and splice-blocking morpholinos, and with control morpholinos (CoMO and spg4CoMO). Time-lapse confocal imaging of axonal EB3-GFP fluorescence was used to monitor microtubule plus-end dynamics (Fig. 3; supplementary material Movies 2-6). Strikingly, in both spastin-morpholino-injected (Fig. 3B,D) and katna1-morpholino-injected (Fig. 3C,E) embryos a near-total loss of discrete puncta of EB3-GFP fluorescence was observed, compared with the situation in control-morpholino-injected embryos (Fig. 3A), where anterograde-moving puncta of fluorescence were observed as in wild-type uninjected embryos. Kymograph analysis revealed that although discrete puncta were absent, a weak anterograde drift of diffuse EB3-GFP fluorescence was still detectable in spastin- and katna1-morphant embryos.

Microtubule-stabilising drugs such as nocodazole and vinblastine have been shown to attenuate synaptic and locomotor phenotypes in Drosophila models of HSP associated with modulation of Dispastin activity (Orso et al., 2005; Trotta et al., 2004). We therefore tested whether immersion of zebrafish embryos in media containing these agents modulated outgrowth of spinal
motor axons in embryos injected with control and spast morpholinos. First, wild-type embryos were exposed continuously to nocodazole at a range of concentrations from 0.1–1.0 µg/ml from 24 hours post-fertilisation (hpf), shortly after the onset of spinal motor axon outgrowth, and then fixed at 30 hpf, towards the end of primary motor axon outgrowth, for immunostaining with znp-1. Over this range of concentrations, nocodazole was found to inhibit axon outgrowth and cause aberrant branching, with a concentration-dependent increase in the severity of the observed outgrowth defects (supplementary material Fig. S5; Table 2). Axons in nocodazole-treated embryos stained robustly with an antibody against acetylated tubulin (results not shown), suggesting that the nocodazole concentrations used do not completely disassemble axonal microtubules. We then tested the effect of the same range of nocodazole concentrations on the axon outgrowth defect caused by reduced spast activity, and observed that immersion of spast-morphant embryos in embryo medium containing nocodazole enhanced the axon outgrowth defect (Fig. 4; Table 3). Lower doses of nocodazole (0.005–0.05 µg/ml) had no discernible effect on axon outgrowth in either control or morphant embryos (results not shown). Zebrafish embryos were remarkably tolerant of vinblastine such that immersion in medium containing 0.01–10 µM vinblastine had no discernible effect on outgrowth of spinal motor axons or on phenotypic severity in spast-morphant embryos (results not shown).

To investigate whether treatment of embryos with nocodazole impaired axonal microtubule dynamics, we exposed NBT:EB3-GFP-injected embryos to nocodazole and performed time-lapse confocal imaging on live anaesthetised embryos (supplementary material Movies 7 and 8). Nocodazole treatment was found to suppress the formation of fluorescent axonal EB3-GFP puncta and to stop all anterograde movement of fluorescent structures (Fig. 5B), in contrast to the situation in DMSO-vehicle-treated control embryos, where vigorous anterograde movement of discrete fluorescent puncta was observed (Fig. 5A).

P60-katanin and spastin are required for growth cone motility

In order to investigate the effects of disrupted microtubule dynamics on the behaviour of growth cones, time-lapse recordings were made of the distal parts of EB3-GFP-expressing neurons in embryos that were injected with spast or katna1 morpholinos, or were treated with nocodazole or DMSO only (supplementary material Movies 9–14). The mean number of outgrowth events per growth cone per minute was calculated from these recordings. Outgrowth events were scored as discrete periods of continuous growth of filopodial processes extending from the growth cone. For those outgrowth events where the process extended for an accurately measurable distance, it was possible to calculate the mean velocity of an outgrowth event by measuring the distance travelled by the tip of the outgrowing process over time. The results of this analysis showed that knockdown of spastin, knockdown of katanin, and treatment of embryos with nocodazole all reduced the number of outgrowth events at growth cones (Fig. 6). These results support the well-established role of normal microtubule function in growth cone motility (Lowery and Van Vactor, 2009),

Table 2. Effect of nocodazole on spinal motor neuron axon outgrowth in wild-type embryos

<table>
<thead>
<tr>
<th>Treatment</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated (n=118)</td>
<td>95.8</td>
<td>3.4</td>
<td>0.8</td>
<td>0</td>
</tr>
<tr>
<td>DMSO control (n=111)</td>
<td>91.9</td>
<td>6.3</td>
<td>1.8</td>
<td>0</td>
</tr>
<tr>
<td>0.1 µg/ml nocodazole (n=108)</td>
<td>17.6</td>
<td>80.6</td>
<td>1.8</td>
<td>0</td>
</tr>
<tr>
<td>0.3 µg/ml nocodazole (n=49)</td>
<td>4.1</td>
<td>73.5</td>
<td>22.4</td>
<td>0</td>
</tr>
<tr>
<td>0.5 µg/ml nocodazole (n=112)</td>
<td>0.9</td>
<td>37.5</td>
<td>61.6</td>
<td>0</td>
</tr>
<tr>
<td>1.0 µg/ml nocodazole (n=118)</td>
<td>0</td>
<td>7.6</td>
<td>79.7</td>
<td>12.7</td>
</tr>
</tbody>
</table>

aData pooled from three independent experiments.
and reveal a novel, direct role of microtubule severing in control of growth cone activity.

**P60-katanin and spastin have different but related functions in axon outgrowth**

Having demonstrated that both *katna1* and *spast* functions promote spinal motor axon outgrowth and are required for normal growth cone motility, and given that their protein products have both been shown to possess microtubule-severing activity and promote the growth of microtubule plus-ends along axons, we set out to determine whether these two proteins function in a concerted manner by comparing the effect of simultaneously knocking down both genes with the effect of knocking down either gene individually. We performed a series of titrations that enabled us to establish individual doses of each morpholino that caused only mild to moderate spinal motor axon outgrowth defects when injected into zebrafish embryos: 93.3% (*n* = 104) with 0.3 pmol *spast* morpholino; and 77.7% (*n* = 85) with 0.9 pmol *katna1aug1* morpholino. When these morpholinos were simultaneously co-injected at these concentrations, a substantially enhanced phenotype was observed, with 58.3% of embryos (*n* = 96) showing severe defects (Fig. 7; Table 4). These qualitative assessments of phenotypic severity were in accord with quantitative measurements of spinal motor axon length that showed mean axon lengths in *spast* and *katna1* morphants were 72% and 63% of those measured in control-injected embryos, whereas the double morphants showed a further reduction to 26% of that in controls (Fig. 7E).

**DISCUSSION**

Our finding that *katna1* is required for axon outgrowth in the zebrafish embryo is consistent with previous work demonstrating that katanin is required for axonal growth by mammalian neurons cultured in vitro (Ahmad et al., 1999; Karabay et al., 2004). This functional overlap in both enzymatic activity and neurobiological function between spastin and katanin suggests that *katna1* could be a potential disease-modifying factor and account for some of the variation in severity and age of onset seen in SPAST HSP cases. The phenotypic enhancement of motor axon outgrowth defects observed in embryos injected with both *spast* and *katna1* morpholinos implies that the microtubule-severing activities of each protein play related roles in axon outgrowth in vivo. Although caution should be shown when interpreting the combined effect of two hypomorphic states, our data clearly demonstrate that levels of katanin activity can influence the motor axon phenotype caused by reduced spastin activity. This finding suggests that the variation in severity and/or age of onset seen in SPAST HSP cases could, at least in part, be determined by levels of katanin activity. Other microtubule-severing proteins such as those encoded by *KATNAL1* and *KATNAL2* might also act as modifiers of spastin function.

Our findings are consistent with the hypothesis of templated nucleation from severed microtubules in axons (Roll-Mecak and Vale, 2006). Although EB3-GFP was found to localise to anterograde-moving comet-like structures in axons of control zebrafish neurons in vivo (Fig. 3A), this behaviour was in marked contrast to the situation in axons of *spast* and *katna1* morphant embryos, where EB3-GFP was still detectable in truncated axons, but the comet-like

---

**Table 3. Effect of nocodazole on spinal motor neuron axon outgrowth in spast-morphant embryos**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Severity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Untreated (<em>n</em> = 46)</td>
<td>89.1</td>
</tr>
<tr>
<td><em>spg4atg1</em> only (<em>n</em> = 74)</td>
<td>0</td>
</tr>
<tr>
<td><em>spg4atg1</em> + DMSO (<em>n</em> = 43)</td>
<td>0</td>
</tr>
<tr>
<td><em>spg4atg1</em> + 0.1 µg/ml nocodazole (<em>n</em> = 78)</td>
<td>0</td>
</tr>
<tr>
<td><em>spg4atg1</em> + 0.3 µg/ml nocodazole (<em>n</em> = 48)</td>
<td>0</td>
</tr>
<tr>
<td><em>spg4atg1</em> + 0.5 µg/ml nocodazole (<em>n</em> = 73)</td>
<td>0</td>
</tr>
<tr>
<td><em>spg4atg1</em> + 1.0 µg/ml nocodazole (<em>n</em> = 80)</td>
<td>0</td>
</tr>
</tbody>
</table>

*Data pooled from three independent experiments.*
structures were completely absent (Fig. 3B–E). Kymograph analysis demonstrated that there was still a generalised anterograde ‘drift’ of diffuse EB3-GFP fluorescence in both spast- and katna1-morphant embryos. This continued anterograde movement of small EB3-GFP-positive particles when spastin and katanin are knocked down could be explained by passive diffusion or transport of free EB3-GFP distally, or uncoordinated movement of individual dynamic microtubules in an anterograde direction. These results suggest that the microtubule-severing activity of spastin and katanin promotes the concerted, coordinated anterograde growth and/or movement of microtubule plus-ends that are decorated with +TIPS such as EB3. This leads to a model in which we suggest that a certain level of microtubule severing facilitates concerted growth of microtubules by creating many co-aligned new plus-ends in one place, the growth of which is then coordinate promotes within the axon (Fig. 8). This hypothesis is supported by evidence that spastin can bundle microtubules in vitro (Salinas et al., 2005), and that bundled microtubules are required for maintenance of axons (Erturk et al., 2007). Owing to the highly dynamic nature of the microtubule network, this concerted growth might ensure that enough microtubules arrive at sites of growth and branching at the same time to provide the physical force to move the tip of the growth cone or branch point forward. Indeed, the fact that the reduction in the number of outgrowth events at the growth cone is equally severe when microtubule severing is reduced and when microtubules are destabilised by nocodazole treatment (Fig. 6) indicates that microtubule severing is vitally important for extension of growth cone filopodial processes. The recent finding by Riano et al. (Riano et al., 2009) that the velocity of EB3-GFP comets is reduced by small interfering RNA (siRNA) knockdown of spastin in the neurites of in vitro cultured neuroblastoma × spinal cord 34 (NSC34) cells further supports the idea that microtubule severing is required for concerted anterograde movement or growth of microtubules. The authors suggest that the decrease in comet velocity observed results from an increased proportion of longer and older microtubules, which can more readily accumulate stabilising post-translational modifications, making them resistant to turnover. The complete loss of comets when spastin is knocked down that we report here could represent a higher sensitivity of zebrafish neurons to loss of microtubule severing, as compared with the neurites of neuron-like cells in vitro, or reflect differences in the efficiencies of morpholinoy and siRNA-mediated knockdown.

Table 4. Effect of simultaneous katna1 and spast knockdown on spinal motor neuron axon outgrowtha

<table>
<thead>
<tr>
<th>Treatment</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uninjected (n=103)</td>
<td>89.3</td>
<td>4.9</td>
<td>5.8</td>
<td>0</td>
</tr>
<tr>
<td>1.2 pmol CoMO (n=101)</td>
<td>81.2</td>
<td>12.9</td>
<td>5.0</td>
<td>0.9</td>
</tr>
<tr>
<td>0.3 pmol spg4atg1 (n=104)</td>
<td>3.8</td>
<td>40.4</td>
<td>52.9</td>
<td>2.9</td>
</tr>
<tr>
<td>0.9 pmol katna1aug1 (n=85)</td>
<td>10.6</td>
<td>50.6</td>
<td>27.1</td>
<td>11.8</td>
</tr>
<tr>
<td>0.3 pmol spg4atg1 + 0.9 pmol katna1aug1 (n=96)</td>
<td>3.1</td>
<td>5.2</td>
<td>33.3</td>
<td>58.3</td>
</tr>
</tbody>
</table>

aData pooled from three independent experiments.
knockdown. More recently, Qiang et al. reported that overexpression of spastin in rat hippocampal neurons increased the number of EB3 comets, but had no effect on mean comet velocity (Qiang et al., 2009). The effect of spastin knockdown on comet number and velocity was not reported in this study.

As was observed when spastin and katanin expression was knocked down, we found that treatment of embryos with nocodazole inhibited axonal outgrowth of spinal motor neurons. However, the results obtained from the live imaging analysis also showed that destabilisation of microtubules with nocodazole prevented all growth and movement of microtubules, because anterograde movement of all EB3-GFP fluorescent material was prevented all growth and movement of microtubules, because anterograde movement of small EB3-GFP-positive particles could be observed even though comet formation was completely inhibited. The difference between the phenotypes of nocodazole-treated embryos and spast or katna1 morphants suggests that loss of microtubule-severing activity might primarily affect the organisation, possibly bundling, of dynamic microtubules, rather than their anterograde movement. We found that administration of nocodazole to spast-morphant embryos did not ameliorate the motor axon outgrowth defects caused by inhibition of spast function. Interestingly, this result contrasts with observations in Drosophila models of SPAST HSP, where microtubule-destabilizing drugs ameliorated both synaptic abnormalities at larval neuromuscular junctions and adult motor defects caused by loss of spastin function (Orso et al., 2005; Trotta et al., 2004). It is unclear how the different effects arise in the different models, but one possibility is that both microtubules and the microtubule-severing activity of spastin perform mechanistically distinct functions in neuromuscular synapses and growing axons. For example, at the neuromuscular junction, stable microtubules could promote neurotransmission by facilitating trafficking of synaptic vesicles. If so, then reduced spastin function would be expected to enhance both microtubule stability and neurotransmission at the Drosophila neuromuscular junction, as was observed. Moreover, administration of the microtubule-destabilizing drug nocodazole would be predicted to suppress neurotransmission, as was also observed. By contrast, if growth of axons and motility of growth cones require dynamic microtubules, then each of these behaviours would be dependent on spastin for production of new microtubule plus-ends, from which growth could then occur. Similarly, disassembly of microtubules by nocodazole, like inhibition of spastin function, would also be expected to impair axon outgrowth and growth cone motility, as was observed in our experiments. Thus, if defective microtubule dynamics in axons and growth cones is a contributory cause of HSP in SPAST cases, then effective therapy might require identification of compounds that stimulate microtubule dynamics.

In conclusion, our results demonstrate that the zebrafish embryo provides a powerful model system for in vivo analysis of microtubule dynamics that is amenable to both genetic and chemical manipulation. Our results also suggest that perturbation of axonal microtubule dynamics might contribute to axonal degeneration in HSP, and that the zebrafish embryo could be useful for identifying compounds that modulate microtubule dynamics in vivo, some of which might be beneficial for treatment of HSP. Although cell culture, fly and mouse models of HSP have been developed, the zebrafish embryo provides new opportunities to combine in vivo analysis of disease mechanisms with
pharmacological manipulations. These practical advantages are not limited to the study of HSP and suggest that further research with zebrafish could help to improve understanding and treatment of a variety of other neurological disorders.

METHODS
Zebrafish maintenance
LWT and AB zebrafish were used for this study, and embryos were obtained by natural mating. All procedures involving experimental animals were performed in compliance with local animal welfare laws, guidelines and policies.

Drug treatments
Stock solutions of nocodazole and vinblastine were prepared in and diluted with DMSO. Drugs in DMSO, and DMSO alone, were added directly to E3 medium containing embryos from 10 or 24 hpf.

DNA constructs
Cloning of human EB3 into pEGFP-N1 is described elsewhere (Stepanova et al., 2003). EB3-GFP cDNA was excised using HindIII and Smal, and placed under control of the Xenopus neural-specific β-tubulin (NBT) promoter by ligating into an NBT:MAPT-GFP vector (constructed by Enrique Amaya, University of Manchester, Manchester, UK; a gift from Chi-Bin Chien, University of Utah Medical Center, UT) from which the MAPT-GFP cDNA had been excised using HindIII and SnaBI.

Microinjection of morpholinos and DNA constructs
All morpholinos were designed by and purchased from Gene Tools, LLC (Philomath, OR). To block katna1 function, morpholino antisense oligonucleotides (MOs) were designed against the initiating AUG of katna1 (katna1aug1, 5'-TCATCTGTGAAAGTTAAAGTGTCAG-3') and against the exon-4—intron-4 splice donor site of katna1 (katna1e4i4, 5'-CACAGATCCTTCCTACCTGTTCTTC-3'). The spast AUG-blocking MO (spag4atg1), spast splice-blocking MO (spgle717) and spast control MO (spg4CoMO) are described elsewhere (Wood et al., 2006). A standard control MO (CoMO) that targets human β-globin pre-mRNA and a morpholino that targets zebrafish p53 were also used. NBT:EB3-GFP was linearised with XbaI prior to injection. Morpholinos (0.3-0.9 mM) and DNA (150 ng/μl) were resuspended in water with Phenol Red, and 2 nl microinjected into one-cell embryos using a Narishige IM-300 microinjector. Embryos were maintained at 28.5°C in E3 medium and dechorionated with fine forceps prior to live imaging or fixation.

Immunoblotting
Total protein was prepared from zebrafish embryos at 29 hpf. Embryos were deyolked by pipetting up and down in deyolking buffer (55 mM NaCl, 1.8 mM NaHCO₃), then washed once in wash buffer (110 mM NaCl, 3.5 mM KCl, 2.7 mM CaCl₂, 10 mM Tris-HCl pH 8.5). Deyolked embryos were prepared for SDS-PAGE by heating for 5 minutes at 100°C in 4 μl SDS-PAGE sample buffer per embryo. SDS-PAGE and immunoblotting were performed using standard procedures. Immunoblots were probed for spastin using S51 (Errico et al., 2004), katna1 using ab67206 (abcam, Cambridge, UK), and α-tubulin using DM1A (Sigma, Poole, UK).

TRANSLATIONAL IMPACT
Clinical issue
The hereditary spastic paraplegias (HSP) are a collection of neurodegenerative disorders characterised by progressive weakness and spasticity of the legs. They are caused by developmental failure or degeneration of motor axons, or nerve fibres, in the corticospinal tract, and are an important cause of permanent disability. Around 40% of autosomal dominant cases of HSP are caused by mutations in the SPAST gene. HSP cases show highly variable age of onset and severity, both between and within families, and haploinsufficiency for SPAST is the likely mechanism in most cases. Current treatments to provide symptomatic relief for HSP include muscle relaxants to relieve spasticity, and physical therapy to maintain muscle strength and range of movement. However, these treatments do not alter or slow the disease, and the development of effective therapies has been hampered by a lack of knowledge regarding the molecular mechanisms underlying axonal degeneration.

Results
Previous work has shown that spastin, the SPAST gene product, shares homology with the p60 subunit of katanin, and both proteins have been shown to be ATP-dependent microtubule-severing proteins. Microtubules, components of the cell’s cytoskeleton, are fundamentally important for the correct outgrowth of axons, but how microtubule-severing activities might relate to axonal degeneration in HSP is unclear. This study uses confocal time-lapse imaging in the zebrafish embryonic CNS to demonstrate that both spastin and katanin are required in axons for the formation of forward-moving dynamic microtubules, and also at the growth cone, the specialised guidance structure at the axon’s growing tip. The effects of lowering the levels of spastin and katanin, mimicking haploinsufficiency, were monitored in embryonic neurons using a fluorescent protein as a marker for the growing microtubules. Reduced expression of either spastin or katanin severely impaired formation of dynamic microtubules and inhibited outgrowth of axons and growth cone motility. The microtubule-destabilising drug nocodazole also abolished microtubule dynamics, suppressed growth cone motility and enhanced the severity of the phenotypes caused by reduced spastin expression in the embryos.

Implications and future directions
These results reveal crucial functions for microtubule-severing proteins in neuronal development, through their roles in dynamic microtubule formation, axonal outgrowth and growth cone protractive activity. SPAST mutations might cause depletion of the pool of dynamic microtubules in neurons, leading to a failure to maintain long axons and the axonal transport machinery within, which could explain the distal axonopathies that are observed in HSP patients. Future studies will aim to identify compounds that modulate microtubule dynamics, which might be of therapeutic value for treatment of HSP.

doi:10.1242/dmm.006197

RT-PCR
Total RNA was isolated from zebrafish embryos at 28 hpf using TRIZOL reagent (Invitrogen). First-strand cDNA was synthesised using SuperSript II (Invitrogen), and a region of katna1 spanning exons 2-6 (nt 243-888) was amplified using the following primers: 5'-AGCTCTGCGGTGGTCTGTTATC-3' and 5'-TCCATGG-GCGTCTTATTCCCT-3'.

Immunostaining of embryos and analysis of axon outgrowth defects
Embryos were fixed with 4% paraformaldehyde at 4°C overnight and immunohistochemistry was performed using standard procedures (Schulte-Merker, 2003). Motor axons were immunostained using monoclonal antibody znp-1 (Developmental Studies Hybridoma Bank, University of Iowa, IA; 1:2000 dilution).
Primary antibody binding was visualised using a VECTASTAIN Elite ABC kit (Vector Laboratories, Burlingame, CA). For qualitative analysis of motor axon outgrowth defects, spinal motor neuron fascicles in ten anterior somites on both sides of the spinal cord were examined using a stereomicroscope and axon outgrowth was scored as follows: 0 = normal, all axons normal; 1 = mild defect, less than 10% of axons aberrantly branched or truncated; 2 = moderate defect, 10-50% of axons aberrantly branched or truncated; 3 = severe defect, more than 50% of axons aberrantly branched or truncated. For quantitative analysis of axon outgrowth defects, spinal motor axons were measured using ImageJ (Rasband, 1997-2007) and an axon measurement plug-in designed and written by R.B. to partially automate the analysis. Mean lengths were calculated and subjected to one-way analysis of variance (ANOVA) with Bonferroni’s multiple comparison test. Statistical analysis was performed using GraphPad Prism software.

Live imaging and analysis of EB3-GFP movements

Embryos (28 hpf) were mounted in 1% low-melting-point agarose containing 0.03% tricaine. Time-lapse recordings of the growth cones and axons of individual neurons were made using an Olympus FV1000 confocal microscope with a 60× water immersion objective (NA 1.2) and a 2× digital zoom applied. Z-stacks were taken every 6 seconds over a 10-minute period. Stacks of images were z-projected and processed using ImageJ (Rasband, 1997-2007). Stacks were aligned using the stackreg plug-in (Thévenaz et al., 1998) and axons were straightened using the straighten plug-in (Kocsis et al., 1991). Kymographs were made using the kymograph plug-in designed and written by R.B. to partially automate kymograph production from straightened stacks and optimise their appearance.

ACKNOWLEDGEMENTS

We are grateful to Tanya Whitfield, Andrew Grierson and Philip Ingham for sharing fish, experimental materials and other reagents, and to Claire Allen, Lisa Gleadall, Susanne Surfleet and Matthew Green for fish care. We are also grateful to Elena Rugarli, University of Cologne, for the kind gift of the anti-spastin SS1 antibody. Funding from the MRC to support the Centre for Developmental and Biomedical Genetics (Grants G0400100 and G0700091 to Philip Ingham) is gratefully acknowledged. The core BMS-MBB Light Microscopy Facility was funded by a grant from The Wellcome Trust (GR077544AIA). This work was funded by a research grant from the Spastic Paraplegia Foundation (http://sp-sca.org) and a research grant from The Wellcome Trust (GR077544AIA). This work was funded by a research grant from The Wellcome Trust (GR077544AIA). This work was funded by a research grant from The Wellcome Trust (GR077544AIA).

REFERENCES